Key result
Perioperative administration of human atrial natriuretic peptide was associated with a significantly lower incidence of post-operative cardiopulmonary complications (26% vs. 86%, P<0.0001).
Why the study?
Does continuous infusion of low-dose human atrial natriuretic peptide reduce post-operative cardiopulmonary complications in elderly patients with elevated pre-operative BNP undergoing pulmonary resection for lung cancer?
Cohort (n=44)
Yes
Does continuous infusion of low-dose human atrial natriuretic peptide reduce post-operative cardiopulmonary complications in elderly patients with elevated pre-operative BNP undergoing pulmonary resection for lung cancer?
Absolute Event Rate: 26% vs 86%
p-value: p=< 0.0001
Continuous infusion of low-dose hANP during lung cancer surgery significantly reduces post-operative cardiopulmonary complications in elderly patients with elevated baseline BNP.
No takes yet. Share an insight, caveat, or question.
Should not yet change practice; hypothesis-generating and warrants randomized confirmation.
Nojiri et al. (2012) conducted a cohort in Lung cancer (n=44). Human atrial natriuretic peptide (hANP) vs. Did not receive hANP was evaluated on Incidence of post-operative cardiopulmonary complications (p=< 0.0001). Perioperative administration of human atrial natriuretic peptide was associated with a significantly lower incidence of post-operative cardiopulmonary complications (26% vs. 86%, P<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: